Search consultations



PHARMAC - Anti-Diabetic Agents

PHARMAC is interested in receiving information from suppliers, clinicians and diabetes healthcare professionals in respect of the following classes of anti-diabetic agents:

a. dipeptidyl peptidase4 inhibitors (DPP4-inhibitors);

b. glucagon-like peptide-1 agonists (GLP-1s);

c. sodium glucose co-transporter 2 inhibitors (SGLT-2s); and

d. combination anti-diabetic agents (e.g. DPP4-inhibitors/metformin).

The purpose of this request for information (RFI) is to seek information to inform and assist PHARMAC in determining the most appropriate funding arrangement and process, which may include progressing to a request for proposals (RFP) or other competitive process at a later date.

See whole document here

Feedback Due: Please send comments to ASAP due date is 1 March 2015

Notify me when this page changes

Enter your email address below to receive alerts when this page is updated.

Sign up below to receive an email when we update this page

Enter the code shown above in the box below.